Site-Specific Glycan Microheterogeneity Evaluation of Aflibercept Fusion Protein by Glycopeptide-Based LC-MSMS Mapping
Abstract
:1. Introduction
2. Results and Discussion
2.1. Identification of Standard Samples (Korea, Europe and USA)
2.2. Quantification of Site-Specific N-Glycopeptides from Standard Samples (Korea, Europe and USA)
3. Materials and Methods
3.1. Materials
3.2. Aflibercept Fusion Protein Samples
3.3. Digestion of Fusion Protein
3.4. LC-MS/MS Analysis
3.5. N-Glycopeptide Identification
3.6. Glycopeptide Quantification
4. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Schjoldager, K.T.; Narimatsu, Y.; Joshi, H.J.; Clausen, H. Global view of human protein glycosylation pathways and functions. Nat. Rev. Mol. Cell Biol. 2020, 21, 729–749. [Google Scholar] [CrossRef] [PubMed]
- Stowell, S.R.; Ju, T.; Cummings, R.D. Protein glycosylation in cancer. Annu. Rev. Pathol. 2015, 10, 473–510. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Van Landuyt, L.; Lonigro, C.; Meuris, L.; Callewaert, N. Customized protein glycosylation to improve biopharmaceutical function and targeting. Curr. Opin. Biotechnol. 2019, 60, 17–28. [Google Scholar] [CrossRef] [PubMed]
- Berger, M.; Kaup, M.; Blanchard, V. Protein glycosylation and its impact on biotechnology. Adv. Biochem. Eng. Biotechnol. 2012, 127, 165–185. [Google Scholar] [CrossRef]
- Hajba, L.; Szekrényes, Á.; Borza, B.; Guttman, A. On the glycosylation aspects of biosimilarity. Drug Discov. Today 2018, 23, 616–625. [Google Scholar] [CrossRef] [Green Version]
- Ackermann, M.; Jäger, V.; Marx, U. Influence of cell- and media-derived factors on the integrity of a human monoclonal antibody after secretion into serum-free cell culture supernatants. Biotechnol. Bioeng. 1995, 45, 97–106. [Google Scholar] [CrossRef]
- Hennicke, J.; Reinhart, D.; Altmann, F.; Kunert, R. Impact of temperature and pH on recombinant human IgM quality attributes and productivity. New Biotechnol. 2019, 50, 20–26. [Google Scholar] [CrossRef]
- Parhiz, H.; Ketcham, S.A.; Zou, G.; Ghosh, B.; Fratz-Berilla, E.J.; Ashraf, M.; Ju, T.; Madhavarao, C.N. Differential effects of bioreactor process variables and purification on the human recombinant lysosomal enzyme β-glucuronidase produced from Chinese hamster ovary cells. Appl. Microbiol. Biotechnol. 2019, 103, 6081–6095. [Google Scholar] [CrossRef]
- Sissolak, B.; Lingg, N.; Sommeregger, W.; Striedner, G.; Vorauer-Uhl, K. Impact of mammalian cell culture conditions on monoclonal antibody charge heterogeneity: An accessory monitoring tool for process development. J. Ind. Microbiol. Biotechnol. 2019, 46, 1167–1178. [Google Scholar] [CrossRef] [Green Version]
- Edwards, E.; Livanos, M.; Krueger, A.; Dell, A.; Haslam, S.M.; Mark Smales, C.; Bracewell, D.G. Strategies to control therapeutic antibody glycosylation during bioprocessing: Synthesis and separation. Biotechnol. Bioeng. 2022, 119, 1343–1358. [Google Scholar] [CrossRef]
- Mimura, Y.; Saldova, R.; Mimura-Kimura, Y.; Rudd, P.M.; Jefferis, R. Importance and Monitoring of Therapeutic Immunoglobulin G Glycosylation; Experientia Supplementum; Springer: Cham, Switzerland, 2021; Volume 112, pp. 481–517. [Google Scholar] [CrossRef]
- Dolashka, P. Tandem mass spectrometry and glycoproteins. In Tandem Mass Spectrometry-Applications and Principles; Prasain, J., Ed.; Intechopen: London, UK, 2012; Chapter 5; pp. 105–126. [Google Scholar]
- An, H.J.; Froehlich, J.W.; Lebrilla, C.B. Determination of glycosylation sites and site-specific heterogeneity in glycoproteins. Curr. Opin. Chem. Biol. 2009, 13, 421–426. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, L. Antibody Glycosylation and Its Impact on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies and Fc-Fusion Proteins. J. Pharm. Sci. 2015, 104, 1866–1884. [Google Scholar] [CrossRef]
- Higel, F.; Seidl, A.; Sörgel, F.; Friess, W. N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins. Eur. J. Pharm. Biopharm. 2016, 100, 94–100. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ruhaak, L.R.; Zauner, G.; Huhn, C.; Bruggink, C.; Deelder, A.M.; Wuhrer, M. Glycan labeling strategies and their use in identification and quantification. Anal. Bioanal. Chem. 2010, 397, 3457–3481. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bongers, J.; Devincentis, J.; Fu, J.; Huang, P.; Kirkley, D.H.; Leister, K.; Liu, P.; Ludwig, R.; Rumney, K.; Tao, L.; et al. Characterization of glycosylation sites for a recombinant IgG1 monoclonal antibody and a CTLA4-Ig fusion protein by liquid chromatography–mass spectrometry peptide mapping. J. Chromatogr. A 2011, 1218, 8140–8149. [Google Scholar] [CrossRef] [PubMed]
- Ciombor, K.K.; Berlin, J.; Chan, E. Aflibercept. Clin. Cancer Res. 2013, 19, 1920–1925. [Google Scholar] [CrossRef] [Green Version]
- Hahm, Y.H.; Lee, J.Y.; Ahn, Y.H. Investigation of Site-Specific Differences in Glycan Microheterogeneity by N-Glycopeptide Mapping of VEGFR-IgG Fusion Protein. Molecules 2019, 24, 3924. [Google Scholar] [CrossRef] [Green Version]
- Zhu, L.; Guo, Q.; Guo, H.; Liu, T.; Zheng, Y.; Gu, P.; Chen, X.; Wang, H.; Hou, S.; Guo, Y. Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry. mAbs 2014, 6, 1474–1485. [Google Scholar] [CrossRef] [Green Version]
- Lee, J.Y.; Lee, H.K.; Park, G.W.; Hwang, H.; Jeong, H.K.; Yun, K.N.; Ji, E.S.; Kim, K.H.; Kim, J.S.; Kim, J.W.; et al. Characterization of Site-Specific N-Glycopeptide Isoforms of α-1-Acid Glycoprotein from an Interlaboratory Study Using LC–MS/MS. J. Proteome Res. 2016, 15, 4146–4164. [Google Scholar] [CrossRef]
- Reusch, D.; Haberger, M.; Falck, D.; Peter, B.; Maier, B.; Gassner, J.; Hook, M.; Wagner, K.; Bonnington, L.; Bulau, P.; et al. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles—Part 2: Mass spectrometric methods. mAbs 2015, 7, 732–742. [Google Scholar] [CrossRef]
- Read, E.K.; Park, J.T.; Brorson, K.A. Industry and regulatory experience of the glycosylation of monoclonal antibodies. Biotechnol. Appl. Biochem. 2011, 58, 213–219. [Google Scholar] [CrossRef] [PubMed]
- Ghaderi, D.; Zhang, M.; Hurtado-Ziola, N.; Varki, A. Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol. Genet. Eng. Rev. 2012, 28, 147–175. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chung, C.H.; Mirakhur, B.; Chan, E.; Le, Q.T.; Berlin, J.; Morse, M.; Murphy, B.A.; Satinover, S.M.; Hosen, J.; Mauro, D.; et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N. Engl. J. Med. 2008, 358, 1109–1117. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ghaderi, D.; Taylor, R.E.; Padler-Karavani, V.; Diaz, S.; Varki, A. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat. Biotechnol. 2010, 28, 863–867. [Google Scholar] [CrossRef] [Green Version]
- Park, G.W.; Kim, J.Y.; Hwang, H.; Lee, J.Y.; Ahn, Y.H.; Lee, H.K.; Ji, E.S.; Kim, K.H.; Jeong, H.K.; Yun, K.N.; et al. Integrated GlycoProteome Analyzer (I-GPA) for Automated Identification and Quantitation of Site-Specific N-Glycosylation. Sci. Rep. 2016, 6, 21175. [Google Scholar] [CrossRef] [Green Version]
- Keller, B.O.; Sui, J.; Young, A.B.; Whittal, R.M. Interferences and contaminants encountered in modern mass spectrometry. Anal. Chim. Acta 2008, 627, 71–81. [Google Scholar] [CrossRef]
- Kronewitter, S.R.; An, H.J.; de Leoz, M.L.; Lebrilla, C.B.; Miyamoto, S.; Leiserowitz, G.S. The development of retrosynthetic glycan libraries to profile and classify the human serum N-linked glycome. Proteomics 2009, 9, 2986–2994. [Google Scholar] [CrossRef] [Green Version]
- Ozohanics, O.; Turiak, L.; Puerta, A.; Vekey, K.; Drahos, L. High-performance liquid chromatography coupled to mass spectrometry methodology for analyzing site-specific N-glycosylation patterns. J. Chromatogr. A 2012, 1259, 200–212. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lee, J.Y.; Choi, J.-W.; Hwang, S.; Hahm, S.H.; Ahn, Y.H. Site-Specific Glycan Microheterogeneity Evaluation of Aflibercept Fusion Protein by Glycopeptide-Based LC-MSMS Mapping. Int. J. Mol. Sci. 2022, 23, 11807. https://doi.org/10.3390/ijms231911807
Lee JY, Choi J-W, Hwang S, Hahm SH, Ahn YH. Site-Specific Glycan Microheterogeneity Evaluation of Aflibercept Fusion Protein by Glycopeptide-Based LC-MSMS Mapping. International Journal of Molecular Sciences. 2022; 23(19):11807. https://doi.org/10.3390/ijms231911807
Chicago/Turabian StyleLee, Ju Yeon, Jin-Woong Choi, Seoyoung Hwang, Sung Ho Hahm, and Yeong Hee Ahn. 2022. "Site-Specific Glycan Microheterogeneity Evaluation of Aflibercept Fusion Protein by Glycopeptide-Based LC-MSMS Mapping" International Journal of Molecular Sciences 23, no. 19: 11807. https://doi.org/10.3390/ijms231911807